Phaarmasia (BSE 523620)₹79.55−2.99%Pharmaceuticals
In the Mar 2026 quarter (standalone), Phaarmasia reported sales of ₹7.70 Cr, up 42.3% from Mar 2025, and net profit of −₹0.71 Cr. For the year to Mar 2026, sales were ₹46.83 Cr and net profit ₹18.02 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.86 | 8.61 | 5.06 | 9.96 | 8.26 | 5.91 | 4.70 | 5.41 | 6.85 | 16.49 | 16.00 | 7.70 |
| Expenses | 7.20 | 8.92 | 5.66 | 9.67 | 8.12 | 6.73 | 5.52 | 6.05 | 6.79 | 14.95 | 15.22 | 8.40 |
| Operating Profit | −0.32 | −0.28 | −0.58 | 0.34 | 0.19 | −0.80 | −0.80 | −0.62 | 0.10 | 1.62 | 0.85 | −0.67 |
| OPM % | −4.5% | −3.1% | −11.3% | 3.3% | 2.2% | −13.4% | −16.8% | −11.3% | 1.3% | 9.7% | 5.2% | −8.6% |
| Other Income | 0.15 | 0.21 | 0.14 | 0.20 | 0.16 | 0.23 | 0.20 | 0.19 | 0.33 | 0.15 | 19.22 | 0.35 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.01 | 0.17 |
| Depreciation | 0.08 | 0.08 | 0.07 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.05 | 0.04 | 0.05 | 0.03 |
| Profit before tax | −0.28 | −0.18 | −0.55 | 0.44 | 0.26 | −0.66 | −0.70 | −0.52 | 0.33 | 1.71 | 19.95 | −0.55 |
| Tax % | 0.0% | −5.9% | 3.7% | −9.4% | −12.1% | 0.0% | 1.4% | 2.0% | 12.4% | −2.4% | 18.2% | 31.4% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.51 | 0.00 |
| Net Profit | −0.28 | −0.17 | −0.57 | 0.48 | 0.29 | −0.65 | −0.71 | −0.54 | 0.28 | 1.75 | 16.31 | −0.71 |
| EPS (Rs) | −0.41 | −0.22 | −0.83 | 0.70 | 0.40 | −0.95 | −1.02 | −0.79 | 0.41 | 2.56 | 23.84 | −1.04 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.96 | 13.95 | 18.94 | 23.93 | 19.93 | 15.96 | 16.95 | 26.91 | 30.90 | 23.91 | 46.83 | 47.04 |
| Expenses | 13.01 | 14.02 | 18.01 | 23.01 | 19.03 | 16.02 | 19.03 | 29.02 | 31.04 | 26.03 | 45.06 | 45.36 |
| Operating Profit | 1.01 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | −2.01 | −2.01 | −1.01 | −2.01 | 2.01 | 1.90 |
| OPM % | 5.0% | 1.0% | 3.5% | 3.0% | 4.1% | −0.4% | −10.0% | −6.0% | −2.7% | −8.0% | 4.0% | 4.0% |
| Other Income | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 | 1.01 | 1.01 | 1.01 | 20.06 | 20.05 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 |
| Profit before tax | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | −2.01 | −1.01 | −1.01 | −2.01 | 21.04 | 21.44 |
| Tax % | 82.9% | 36.9% | 15.9% | 6.0% | 45.0% | 33.0% | −1.0% | −12.1% | −6.1% | −1.0% | 17.9% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.06 | 15.51 |
| Net Profit | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | −2.01 | −1.01 | −1.01 | −2.01 | 18.02 | 17.63 |
| EPS (Rs) | 0.07 | 0.24 | 0.84 | 1.13 | 0.80 | 0.46 | −2.28 | −1.84 | −0.77 | −2.34 | 25.78 | 25.77 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.02 | 7.01 | 7.01 | 7.00 | 6.99 | 6.99 | 7.00 | 7.01 | 6.99 | 6.99 | 6.99 | 7.01 |
| Reserves | 6.02 | 5.01 | 5.00 | 5.00 | 5.99 | 6.98 | 7.00 | 5.00 | 3.99 | 2.99 | 1.99 | 15.00 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| Other Liabilities | 6.02 | 7.04 | 8.04 | 10.05 | 20.09 | 20.08 | 8.04 | 9.04 | 17.06 | 21.07 | 13.06 | 7.03 |
| Total Liabilities | 19.06 | 19.06 | 20.05 | 22.05 | 33.07 | 34.05 | 22.04 | 21.05 | 28.04 | 31.05 | 22.04 | 30.04 |
| Fixed Assets | 16.05 | 14.05 | 14.04 | 14.04 | 14.04 | 13.03 | 13.03 | 13.04 | 13.03 | 12.04 | 12.03 | 1.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 4.01 | 5.01 | 6.01 | 8.01 | 19.03 | 20.02 | 9.01 | 8.01 | 16.01 | 19.01 | 9.01 | 29.03 |
| Inventories | 1.30 | 0.20 | 1.04 | 1.30 | 5.98 | 6.09 | 2.64 | 4.25 | 6.37 | 8.51 | 3.07 | 4.37 |
| Trade receivables | 1.62 | 2.92 | 3.57 | 3.80 | 11.81 | 12.36 | 4.28 | 3.20 | 7.54 | 8.08 | 3.12 | 5.15 |
| Cash & equivalents | 0.27 | 0.43 | 0.14 | 0.18 | 0.18 | 0.14 | 0.37 | 0.21 | 0.68 | 0.62 | 0.35 | 10.95 |
| Total Assets | 19.06 | 19.06 | 20.05 | 22.05 | 33.07 | 34.05 | 22.04 | 21.05 | 28.04 | 31.05 | 22.04 | 30.04 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 1.01 | — | — | 1.01 | — | — | −16.01 |
| Cash from investing activity | — | — | — | −1.01 | — | — | 0.00 | — | — | 26.06 |
| Cash from financing activity | — | — | — | 0.00 | — | — | 0.00 | — | — | 1.01 |
| Net cash flow | — | — | — | 0.00 | — | — | 0.00 | — | — | 11.03 |
| Capex | 0.36 | 0.29 | 0.08 | 0.91 | 0.13 | 0.00 | 0.04 | 0.04 | 0.18 | 0.00 |
| Free cash flow | — | — | — | 0.00 | — | — | 0.99 | — | — | 8.99 |
| CFO / OP % | — | — | — | 153.0% | — | — | −42.0% | — | — | −878.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 48 | 78 | 91 | 73 | 179 | 226 | 96 | 69 | 100 | 96 | 47 | 40 |
| Inventory days | 80 | 12 | 56 | 43 | 135 | 125 | 66 | 112 | 103 | 126 | 57 | 48 |
| Days payable | 185 | 216 | 293 | 249 | 403 | 374 | 166 | 214 | 269 | 298 | 224 | 23 |
| Cash conversion cycle | −55 | −126 | −145 | −132 | −88 | −23 | −3 | −32 | −64 | −75 | −119 | 65 |
| Working capital days | −79 | −64 | −43 | −34 | −13 | 7 | 8 | −17 | −39 | −43 | −71 | 62 |
| ROCE % | 3.0% | 2.0% | 2.0% | 6.0% | 7.0% | 8.0% | 4.0% | −12.1% | −12.0% | −5.0% | −16.1% | 15.9% |
For the Mar 2026 quarter, Phaarmasia reported sales of ₹7.70 Cr, up 42.3% year on year and net profit of −₹0.71 Cr. The operating margin was −8.6%.
Phaarmasia's sales for the year to Mar 2026 were ₹46.83 Cr; over the last twelve months they were ₹47.04 Cr.
Net profit for the year to Mar 2026 was ₹18.02 Cr, and ₹17.63 Cr over the last twelve months. Earnings per share over the same trailing period were ₹25.77.
Phaarmasia reported borrowings of ₹1 Cr at Mar 2026, against cash and equivalents of ₹10.95 Cr.
Cash from operations was −₹16.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹8.99 Cr.